Arjen Joosse

1.4k total citations
33 papers, 959 citations indexed

About

Arjen Joosse is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Arjen Joosse has authored 33 papers receiving a total of 959 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Arjen Joosse's work include Cancer Immunotherapy and Biomarkers (16 papers), Cutaneous Melanoma Detection and Management (13 papers) and CAR-T cell therapy research (5 papers). Arjen Joosse is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Cutaneous Melanoma Detection and Management (13 papers) and CAR-T cell therapy research (5 papers). Arjen Joosse collaborates with scholars based in Netherlands, United States and Germany. Arjen Joosse's co-authors include Tamar Nijsten, Esther de Vries, Alexander M.M. Eggermont, J.W.W. Coebergh, Sandra Collette, Stefan Suciu, Renate Eckel, Jutta Engel, D. Hölzel and M. K. Casparie and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Arjen Joosse

30 papers receiving 953 citations

Peers

Countries citing papers authored by Arjen Joosse

Since Specialization

Citations

This map shows the geographic impact of Arjen Joosse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arjen Joosse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arjen Joosse more than expected).

Fields of papers citing papers by Arjen Joosse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arjen Joosse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arjen Joosse. The network helps show where Arjen Joosse may publish in the future.

Co-authorship network of co-authors of Arjen Joosse

This figure shows the co-authorship network connecting the top 25 collaborators of Arjen Joosse. A scholar is included among the top collaborators of Arjen Joosse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arjen Joosse. Arjen Joosse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comprehensive characterization of circulating tumor cells and cell‐free DNA in patients with metastatic melanoma 2024 ·Molecular Oncology ·(unknown), Jaco Kraan, Martijn P. A. Starmans, Jean Helmijr, (unknown), Maja J.A. de Jonge, Arjen Joosse, Astrid A.M. van der Veldt, Peter A.W. te Boekhorst, John W.M. Martens, Stefan Sleijfer, Saskia M. Wilting	1
2	From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting 2024 ·BMC Cancer ·(unknown), Astrid A.M. van der Veldt, Marlies Wakkee, (unknown), (unknown), Margot Joosen, Arjen Joosse, Karlijn de Joode, Tamar Nijsten, Marjolein Lugtenberg	1
3	Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report 2023 ·Journal for ImmunoTherapy of Cancer ·Karlijn de Joode, Sharon Veenbergen, (unknown), (unknown), Reno Debets, Ron H.J. Mathijssen, Arjen Joosse, Marco W.J. Schreurs, Astrid A.M. van der Veldt	4
4	Impact of Novel Treatments in Patients with Melanoma Brain Metastasis: Real-World Data 2023 ·Cancers ·(unknown), Joost L.M. Jongen, (unknown), (unknown), (unknown), Arjen Joosse, Maja J.A. de Jonge, Joost W. Schouten, Esther Oomen‐de Hoop, Martin J. van den Bent, Astrid A.M. van der Veldt	2
5	Oncological healthcare providers’ perspectives on appropriate melanoma survivorship care: a qualitative focus group study 2023 ·BMC Cancer ·(unknown), Marlies Wakkee, (unknown), Astrid A.M. van der Veldt, Arjen Joosse, (unknown), Peter W. Plaisier, Tamar Nijsten, Marjolein Lugtenberg	5
6	1154P Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors 2023 ·Annals of Oncology ·(unknown), (unknown), (unknown), Esther Oomen‐de Hoop, Karlijn de Joode, Sander Bins, Stijn L.W. Koolen, Arjen Joosse, Jorie Versmissen, Astrid A.M. van der Veldt, Ron H.J. Mathijssen	1
7	Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma 2022 ·British Journal of Dermatology ·(unknown), Astrid A.M. van der Veldt, Margot Joosen, Karlijn de Joode, Arjen Joosse, Dirk J. Grünhagen, Tamar Nijsten, Marlies Wakkee, Marjolein Lugtenberg	20
8	The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma 2022 ·ESMO Open ·(unknown), Karlijn de Joode, Evalyn E.A.P. Mulder, (unknown), Arjen Joosse, Maja J.A. de Jonge, Cornelis Verhoef, Dirk J. Grünhagen, Marion Smits, Martin J. van den Bent, Astrid A.M. van der Veldt	4
9	Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study 2022 ·European Journal of Cancer ·Edwin A. Basak, (unknown), Karlijn de Joode, Daan P. Hurkmans, (unknown), Esther Oomen‐de Hoop, Marco W.J. Schreurs, Sander Bins, Stijn L.W. Koolen, Reno Debets, Astrid A.M. van der Veldt, Joachim G.J.V. Aerts, Arjen Joosse, Ron H.J. Mathijssen	13
10	The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy 2022 ·Biomedicine & Pharmacotherapy ·Edwin A. Basak, Karlijn de Joode, (unknown), (unknown), Marco W.J. Schreurs, Sjoerd A.A. van den Berg, Esther Oomen‐de Hoop, Cor H. van der Leest, Layal Chaker, Richard A. Feelders, Astrid A.M. van der Veldt, Arjen Joosse, Stijn L.W. Koolen, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Sander Bins	4
11	Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients 2020 ·Thyroid ·Edwin A. Basak, (unknown), Daan P. Hurkmans, Marco W.J. Schreurs, Esther Oomen‐de Hoop, Astrid A.M. van der Veldt, Sander Bins, Arjen Joosse, Stijn L.W. Koolen, Reno Debets, Robin P. Peeters, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Marco Medici	64
12	Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment 2019 ·Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans, (unknown), (unknown), Karin Boer, Arjen Joosse, Carla C. Baan, Jan H. von der Thüsen, Ron H. N. van Schaik, Ron H.J. Mathijssen, Astrid A.M. van der Veldt, Dennis A. Hesselink	30
13	Sex Differences in Melanoma Survival are Not Related to Mitotic Rate of the Primary Tumor 2014 ·Annals of Surgical Oncology ·Arjen Joosse, Augustinus P. T. van der Ploeg, Lauren E. Haydu, Tamar Nijsten, Esther de Vries, Richard A. Scolyer, Alexander M.M. Eggermont, J.W.W. Coebergh, John F. Thompson	15
14	Statin use and its effect on all‐cause mortality of melanoma patients: a population‐based Dutch cohort study 2014 ·Cancer Medicine ·Elisabeth Livingstone, Loes M. Hollestein, Myrthe P. P. van Herk‐Sukel, Lonneke van de Poll‐Franse, Arjen Joosse, Bastian Schilling, Tamar Nijsten, Dirk Schadendorf, Esther de Vries	26
15	Sunny Holidays before and after Melanoma Diagnosis Are Respectively Associated with Lower Breslow Thickness and Lower Relapse Rates in Italy 2013 ·PLoS ONE ·Sara Gandini, Esther de Vries, Giulio Tosti, Edoardo Botteri, Giuseppe Spadola, Patrick Maisonneuve, Chiara Martinoli, Arjen Joosse, Pier Francesco Ferrucci, Federica Baldini, Emilia Cocorocchio, Elisabetta Pennacchioli, F Cataldo, Barbara Bazolli, (unknown), Massimo Barberis, Véronique Bataille, Alessandro Testori	9
16	Gender Differences in Melanoma Survival: Female Patients Have a Decreased Risk of Metastasis 2010 ·Journal of Investigative Dermatology ·Arjen Joosse, Esther de Vries, Renate Eckel, Tamar Nijsten, Alexander M.M. Eggermont, D. Hölzel, J.W.W. Coebergh, Jutta Engel	196
17	Reactive oxygen species and melanoma: an explanation for gender differences in survival? 2010 ·Pigment Cell & Melanoma Research ·Arjen Joosse, Esther de Vries, Casper H.J. van Eijck, Alexander M.M. Eggermont, Tamar Nijsten, J.W.W. Coebergh	50
18	Non-Steroidal Anti-Inflammatory Drugs and Melanoma Risk: Large Dutch Population-Based Case–Control Study 2009 ·Journal of Investigative Dermatology ·Arjen Joosse, (unknown), M. K. Casparie, Ron M. C. Herings, Henk‐Jan Guchelaar, Tamar Nijsten	34
19	Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case–control study 2008 ·Annals of Oncology ·E.R. Koomen, Arjen Joosse, Ron M. C. Herings, M. K. Casparie, Henk‐Jan Guchelaar, Tamar Nijsten	61
20	Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? 2007 ·European Journal of Cancer ·E.R. Koomen, Arjen Joosse, Ron M. C. Herings, M. K. Casparie, W. Bergman, Tamar Nijsten, Henk‐Jan Guchelaar	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact